SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors

SystImmune and Bristol Myers Squibb announced the first global Phase I results of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjuga...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricingFinancial solutions
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/SystImmune and Bristol Myers Squibb Announce Phase I Results of Iza-bren (EGFR x HER3 ADC) in Advanced Solid Tumors